Efficacy of oral etoposide in patients with platinum and taxane-resistant intensively pretreated ovarian cancer

被引：0
|
作者：
Makhnova, Elena V. [1 ]
Gershanovich, Michael L. [1 ]
机构：
[1] NN Petrov Oncol Res Inst, St Petersburg, Russia
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：128 / 129
页数：2
相关论文
共 50 条
  • [31] Akt inhibition improves the efficacy of cabazitaxel nanomedicine in preclinical taxane-resistant cancer models
    Li, Tongyu
    Chen, Xiaona
    Wan, Jianqin
    Hu, Xiaoxiao
    Chen, Wanzhi
    Wang, Hangxiang
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 607
  • [32] Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC)
    Alici, S
    Saip, P
    Eralp, YI
    Aydiner, A
    Topuz, E
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (04): : 358 - 362
  • [33] Altretamine (hexalen) and gemcitabine (gemzar) versus altretamine (hexalen) and etoposide (vepesid) in platinum-taxane resistant ovarian cancer
    Gorbounova, V
    Bluymenberg, A
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 385 - 385
  • [34] Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer
    Bunnell, Craig
    Vahdat, Linda
    Schwartzberg, Lee
    Gralow, Julie
    Klimovsky, Judith
    Poulart, Valerie
    Peck, Ronald
    Thomas, Eva
    CLINICAL BREAST CANCER, 2008, 8 (03) : 234 - 241
  • [35] Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
    De Geest, Koen
    Blessing, John A.
    Morris, Robert T.
    Yamada, S. Diane
    Monk, Bradley J.
    Zweizig, Susan L.
    Matei, Daniela
    Muller, Carolyn Y.
    Richards, William E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 149 - 153
  • [36] SEQUENTIAL MAINTENANCE CHEMOTHERAPY WITH TAXANE AND ORAL ETOPOSIDE FOR ADVANCED OVARIAN CANCER AND PERITONEAL CANCER
    Nagano, H.
    Kawakami, M.
    Ueno, M.
    Kawahara, K.
    Muraoka, M.
    Takagi, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [37] Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer
    Bozkaya, Yakup
    Dogan, Mutlu
    Erdem, Gokmen Umut
    Tulunay, Gokhan
    Uncu, Hikmet
    Arik, Zafer
    Demirci, Umut
    Yazici, Ozan
    Zengin, Nurullah
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2017, 37 (05) : 649 - 654
  • [38] Oral etoposide administration following taxane as maintenance chemotherapy for advanced ovarian cancer
    Nagano, H.
    Yasunari, T.
    Kawakami, M.
    Ueno, M.
    Morita, Y.
    Muraoka, M.
    Takagi, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 789 - 789
  • [39] Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study
    Huang, Qi
    Chu, Chaonan
    Tang, Jie
    Dai, Zhijie
    JOURNAL OF CANCER, 2020, 11 (18): : 5353 - 5358
  • [40] Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: A NSGO study
    Kristensen, G.
    Kaern, J.
    Baekelandt, M.
    Skeie-Jensensen, T.
    Christensen, R. dePont
    Avall-Lundqvist, E.
    Bergdahl, M.
    Sandvei, R.
    Hoegberg, T.
    Grenmann, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345